Akebia Therapeutics
Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing therapies for kidney disease. Its lead product is Auryxia, a ferric citrate used to control serum phosphorus in adult patients with chronic kidney disease on dialysis or with hyperphosphatemia, and vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor studied for treating anemia due to CKD in both dialysis-dependent and non-dialysis patients. The company collaborates with Otsuka Pharmaceutical for vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other regions; with Mitsubishi Tanabe Pharma for the development and commercialization of vadadustat in Japan and other Asian countries; and with Janssen Pharmaceutica for worldwide development and commercialization of HIF-prolyl hydroxylase-targeted compounds. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Top Stages
1 past transactions
Keryx Biopharmaceuticals
Acquisition in 2018
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts, specializing in the development and commercialization of treatments for kidney diseases. The company's primary product, Auryxia, is an orally administered, iron-based medication designed to manage serum phosphorus levels in patients with chronic kidney disease (CKD) undergoing dialysis, as well as to treat iron deficiency anemia in adults with CKD who are not on dialysis. Keryx Biopharmaceuticals is committed to supporting independent research and provides resources such as co-pay assistance and patient support programs. The company was founded in 1997 and has established strategic partnerships for the development and commercialization of its products in various markets, including collaborations with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for Auryxia in Japan. As of December 2018, Keryx operates as a subsidiary of Akebia Therapeutics, Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.